IRIS
CARACCIOLO, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.701
AS - Asia 1.063
EU - Europa 800
SA - Sud America 223
Continente sconosciuto - Info sul continente non disponibili 147
AF - Africa 26
OC - Oceania 3
Totale 3.963
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.642
SG - Singapore 490
IT - Italia 484
CN - Cina 246
BR - Brasile 169
DE - Germania 101
IN - India 97
VN - Vietnam 88
GB - Regno Unito 72
HK - Hong Kong 46
CA - Canada 38
SE - Svezia 35
FI - Finlandia 34
BD - Bangladesh 23
NL - Olanda 19
MX - Messico 14
ID - Indonesia 13
AR - Argentina 12
FR - Francia 11
ZA - Sudafrica 11
EC - Ecuador 10
JP - Giappone 9
RU - Federazione Russa 9
VE - Venezuela 8
ES - Italia 7
EU - Europa 7
AT - Austria 6
CO - Colombia 6
IQ - Iraq 6
PY - Paraguay 6
UZ - Uzbekistan 6
CL - Cile 5
KE - Kenya 5
PK - Pakistan 5
TR - Turchia 5
UA - Ucraina 5
CZ - Repubblica Ceca 4
JO - Giordania 4
AU - Australia 3
CH - Svizzera 3
EG - Egitto 3
LB - Libano 3
NP - Nepal 3
PE - Perù 3
PL - Polonia 3
SC - Seychelles 3
AZ - Azerbaigian 2
ET - Etiopia 2
IR - Iran 2
LT - Lituania 2
MA - Marocco 2
OM - Oman 2
SA - Arabia Saudita 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CR - Costa Rica 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
IE - Irlanda 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LV - Lettonia 1
MM - Myanmar 1
MY - Malesia 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 3.823
Salva come PNG Salva come JPEG
Città #
San Jose 309
Singapore 216
Ashburn 169
Chandler 152
Santa Clara 83
Dallas 79
Munich 71
Bengaluru 66
Hefei 66
Beijing 57
Council Bluffs 55
Chicago 50
London 50
Catanzaro 46
Lawrence 44
Milan 44
Princeton 44
Hong Kong 42
Ho Chi Minh City 31
Naples 26
Hanoi 23
Turku 22
Los Angeles 20
Wilmington 18
New York 17
Rome 17
São Paulo 16
Parma 14
Des Moines 13
Ottawa 13
Brooklyn 12
Carbonia 12
Helsinki 12
Montreal 11
Boardman 9
Cosenza 8
Ercolano 8
Redwood City 8
San Nicola Manfredi 8
Santo Stefano di Rogliano 8
Afragola 7
Aversa 7
Boston 7
Bologna 6
Catania 6
Dhaka 6
Manchester 6
Melito di Porto Salvo 6
Reggio Calabria 6
Shanghai 6
Stockholm 6
Tashkent 6
Charlotte 5
Chennai 5
Columbus 5
Denver 5
Guangzhou 5
Mexico City 5
Nairobi 5
Orem 5
Seattle 5
Settingiano 5
The Dalles 5
Amman 4
Brescia 4
Buffalo 4
Can Tho 4
Da Nang 4
Decollatura 4
Frankfurt am Main 4
Haiphong 4
Hanover 4
Jakarta 4
Jiaxing 4
Johannesburg 4
Mountain View 4
New Delhi 4
Phoenix 4
Pune 4
Redmond 4
Rio de Janeiro 4
San Francisco 4
Thái Bình 4
Tokyo 4
Acquaviva delle Fonti 3
Ahmedabad 3
Atlanta 3
Belo Horizonte 3
Berlin 3
Biên Hòa 3
Cape Town 3
Castrovillari 3
Guayaquil 3
Las Vegas 3
Madrid 3
Manaus 3
Mileto 3
Nova Iguaçu 3
Nuremberg 3
Olomouc 3
Totale 2.231
Salva come PNG Salva come JPEG
Nome #
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 146
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 119
miR-22 suppresses DNA ligase III addiction in multiple myeloma 108
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 100
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 98
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 89
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 89
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 83
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 79
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 78
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 77
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 77
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 76
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 75
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 74
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 74
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 74
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 71
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 69
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 68
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 67
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 65
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma 61
Mir-221/222 are promising targets for innovative anticancer therapy 61
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 61
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 60
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 60
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 59
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 59
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 58
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 58
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 57
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 57
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 56
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma 55
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 55
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 53
Integration of DNA Microarray with Clinical and Genomic Data 53
Mmrf-commpass data integration and analysis for identifying prognostic markers 52
Mirnas and lncrnas as novel therapeutic targets to improve cancer immunotherapy 52
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 51
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity 51
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 50
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 48
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma 47
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology 47
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 45
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 45
Alternative non-homologous end-joining: Error-prone dna repair as cancer’s achilles’ heel 45
null 43
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 42
The potential role of miRNAs in multiple myeloma therapy 40
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 38
Tools in Pharmacogenomics Biomarker Identification for Cancer Patients 37
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 37
The potential role of miRNAs in multiple myeloma therapy 35
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. 35
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches 34
TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects 31
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma 31
null 31
Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment. 28
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy 28
Synthetic miR-22 impairs NHEJ repair sensistizing multiple myeloma cells to bortezomib-induced BRCAness 27
Targeting oncogenic pri-miR-17-92 in multiple myeloma: molecular findings and therapeutic potential 27
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 26
Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase 18
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 14
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 12
UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager 11
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 11
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort 6
PARP1 trapping activates cGAS-STING pathway to induce immunogenic cell death in multiple myeloma 6
Clinical outcomes of the chemo‐free approach in relapsed/refractory follicular lymphoma: A network meta‐analysis 3
Totale 3.963
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.161
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.161
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022175 0 0 0 27 7 5 11 30 37 31 24 3
2022/2023541 95 29 32 21 64 38 6 39 76 54 68 19
2023/2024320 86 32 36 22 16 83 7 6 1 5 10 16
2024/2025886 88 26 29 37 59 132 39 45 70 10 130 221
2025/20261.761 111 184 168 227 196 84 244 83 211 153 69 31
2026/202795 21 74 0 0 0 0 0 0 0 0 0 0
Totale 3.963